SynVivo provides a cell-based microfluidic organ-on-chip platform for studying cellular behavior, drug delivery, and drug discovery in a biologically realistic microenvironment. This technology links microfluidics and bioengineering.

SynVivo

InSphero provides 3D in vitro models and solutions designed for drug safety and efficacy testing, enabling researchers to transition from animal testing. The company offers reliable and scalable cell culture models.

InSphero

SynVivo, Inc | 1,280 followers on LinkedIn. 3D Tissue and Organ-on-Chip Models | SynVivo is a 3D Tissue and Organ-on-Chip developer whose models accelerate real-time studies of cellular behavior, drug delivery, and drug discovery by providing a biologically realistic microenvironment that more accurately depicts in vivo reality. SynVivo&#39;s models recreate complex in vivo microvasculature including scale, morphology, hemodynamic shear stress, and cellular interactions in an in vitro microfluidic chip environment and enable real-time visualization and quantitation.

SynVivo&#39;s proprietary microfluidic technology links the high-tech domains of microfluidics and bioengineering for broad applications in the life science arena.

Chairman at SynVivo; Executive VP at CFD Research

Kapil Pant

Product Marketing Specialist at SynVivo inc.

Nicole Poore

President and CEO at SynVivo, Inc

Gwen Fewell

Research Scientist at SynVivo Inc Ph.D in Pharmaceutical Sciences | Research work focused on Cancer biology, Immuno-oncology and Bioprinting

Shreyas Gaikwad

SynVivo, Inc

🎉 Exciting News! We're proud to partner with Axoltis Pharma on their latest publication, showcasing innovative research using organ-on-a-chip technology! This study highlights how our SynBBB Blood-Brain-Barrier-on-a-Chip can advance understanding of the blood-brain barrier, including testing therapeutic candidates paving the way for breakthroughs in various neurological disorders with current unmet need. Congratulations to the Axoltis Team! #synvivobio #SynBBB #NX210c #BBB #ALS

SynVivo is excited to be attending the Society for Neuroscience conference in Chicago. We will be hosting one-on-one meetings to discuss our SynBBB Blood-Brain-Barrier model, CRO services offerings, and training workshops. If you are interested in scheduling a meeting with our team, please share your availability via our contact form ( https://lnkd.in/gAjrypiQ ). #SynVivo #OrganChip #BBB #SfN2024

Animal models may not be transposable to humans, and in cancer research, this can compromise accuracy...😔 What if you had a tool that truly mimics human tumor environments? 💭 We are happy to present the SynTumor 3D Cancer Model from SynVivo, Inc ! 🎉 This new chip reproduces realistic tumor environments, reaching a level of complexity close to that of the human body. And thanks to its unique vascularised network design, you can get real insights into how drugs interact with tumor cells! Ready to accelerate your research? 😁 Check out the details and see how SynTumor can change your approach to cancer research: https://lnkd.in/eR4rPYqD 👩🔬👨🔬 #cancermodeling #drugscreening #microbiology

Darwin Microfluidics

Vascular geometry and perfusion status of vasculature surrounding tumors can impact drug delivery and efficacy. Create in vivo-like tumor heterogeneity and vascularization to test drug delivery, efficacy, metastasis and anti-cancer therapeutics with the SynTumor -on-Chip platform. Key Features and Benefits: 1. Microvascular Networks: SynTumor -on-Chip incorporates realistic, perfusable vascular networks, which are crucial for mimicking the blood flow and nutrient supply in tumors. This feature allows for the study of drug delivery and distribution within a tumor, mirroring the in vivo conditions more closely. 2. 3D Tumor Microenvironment: The platform supports the growth of tumor cells in a three-dimensional structure, which better replicates actual tumor architecture and cell-cell interactions found in the human body. This 3D environment is critical for understanding how tumors grow, invade surrounding tissues, and respond to therapies. 3. Real-Time Monitoring: The technology allows for continuous observation and analysis of tumor behavior and drug effects in real time. This capability provides dynamic insights into the mechanisms of drug action, resistance, and tumor progression. 4. Customizability: SynTumor -on-Chip can be tailored to model specific types of cancers, making it a versatile tool for research on different tumor types and for personalized medicine approaches. Researchers can recreate specific tumor microenvironments to study targeted therapies and personalized treatment strategies. 5. Reduced Animal Testing: By offering a more accurate representation of human tumors, SynTumor-on-Chip has the potential to reduce reliance on animal models in preclinical testing. This aligns both with the 3Rs mission and enhances the predictive power of preclinical studies. Learn more and explore publications at https://lnkd.in/gecgeBsp . #SynTumor #Synvivobio #SynVivo

The blood-brain-barrier is a highly selective barrier protecting the brain from foreign matter. Its remarkable effectiveness also poses a significant challenge in delivering therapeutics to treat central nervous system diseases. SynVivo has developed a physiologically relevant human blood-brain-barrier-on-a-chip to assess permeability of drugs, neuroinflammation and therapeutic screening. Find more details and publications at https://lnkd.in/g6xpxDJN #SynVivo #synvivobio #SynBBB #bloodbrainbarrier

We’re already on day 3 at the MPS World Summit! Day 1 kicked off with a packed hands-on sessions in our educational workshop led by Deborah Ramsey, Ph.D., followed by two fantastic days of discussing all things MPS at booth #87. If you haven't had a chance yet, there's still time to meet with our team and learn more about our offerings or check out one of our poster presentations. Poster 183: Small Airway Lung-on-Chip Model for evaluating neutrophil - mediated damaged in inflamed lung tissues Poster 328: Blood-Brain-Barrier-on-Chip models for more predictive in vitro modeling of Receptor Mediated Transcytosis

Join Gwen Fewell , Deborah Ramsey, Ph.D. and Grace McGrew this week at the MPS World Summit. Visit us at SynVivo's booth #87, join our session at the Educational Workshop, or meet us at one of our poster presentations. We look forward to seeing you there! #SynVivo #synvivobio #MPSWorldSummit2024 #OrganChip

We're excited to be exhibiting at the MPS World Summit in Seattle, Washington. Visit us at our booth, attend our session at the Educational Workshop, or visit our poster presentations on Blood-Brain-Barrier and Lung ALI-on-Chip models. We can't wait to connect with you there! #SynVivo #synvivobio #OrganChip #MPSWorldSummit2024

Come visit us at AACR Booth #117. We are excited to discuss our vascularized tumor-on-chip models for your oncology applications. #AACR2024 Deborah Ramsey, Ph.D. Gwen Fewell #SynVivo #tumoronchip

Metric
Company Name	SynVivo	InSphero
Symbol
MSH ID	COM:SYNVIVOBIO	COM:INSPHERO
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology
Country	US	CH
Stage
Employee Count
Website	synvivobio.com	insphero.com
LinkedIn	synvivo
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	170
Web Traffic Growth	-0.51
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

SYNV

COM:SYNVIVOBIO

SynVivo

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue